What does CUSIP 00972D105 represent in this 13F holders report?

CUSIP 00972D105 is the security identifier for AKBA - Akebia Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held AKBA - Akebia Therapeutics, Inc. - Common Stock in Q3 2022?

79 institutional investors reported AKBA - Akebia Therapeutics, Inc. - Common Stock for Q3 2022. Use the holders table for investor-level position and value details.

Akebia Therapeutics, Inc. - Common Stock (AKBA)

CUSIP: 00972D105

Q3 2022 13F Holders as of 30 Sep 2022

Type / Class: Equity / Common Stock
Shares outstanding: 263,222,327
Total 13F shares: 52,161,214
Share change: -5,580,388
Total reported value: $16,491,885
Put/Call ratio: 48%
Price per share: $0.32
Number of holders: 79
Value change: -$1,812,681
Number of buys: 24
Number of sells: 46

Quarterly Holders Quick Answers

What is CUSIP 00972D105?
CUSIP 00972D105 identifies AKBA - Akebia Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2022
Previous quarter: Q2 2022

Recent filing periods for CUSIP 00972D105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AKBA - Akebia Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
VANGUARD GROUP INC	13F	Company	6.2%	16,259,104	$5,741,000	—	30 Jun 2022	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	2.8%	7,339,043	$2,592,000	—	30 Jun 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	2%	5,354,175	$1,891,000	—	30 Jun 2022	13F
Alerce Investment Management, L.P.	13F	Company	1.8%	4,652,561	$1,642,000	—	30 Jun 2022	13F
BlackRock Finance, Inc.	13F	Company	1.6%	4,340,026	$1,531,000	—	30 Jun 2022	13F
FEDERATED HERMES, INC.	13F	Company	0.76%	1,989,467	$702,000	—	30 Jun 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.61%	1,617,393	$571,000	—	30 Jun 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.56%	1,482,300	$523,000	—	30 Jun 2022	13F
HRT FINANCIAL LP	13F	Company	0.42%	1,103,737	$389,000	—	30 Jun 2022	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.33%	862,168	$304,000	—	30 Jun 2022	13F
Ergoteles LLC	13F	Company	0.32%	849,000	$300,000	—	30 Jun 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.3%	782,675	$276,000	—	30 Jun 2022	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.3%	777,617	$275,000	—	30 Jun 2022	13F
Violetta Cotreau	3/4/5	SVP, Chief Accounting Officer	— class O/S missing	219,954	$268,982	—	12 May 2022	3/4/5
MORGAN STANLEY	13F	Company	0.25%	655,867	$232,000	—	30 Jun 2022	13F
FMR LLC	13F	Company	0.24%	621,244	$219,000	—	30 Jun 2022	13F
Dell J. Faulkingham	3/4/5	SVP, CCO	— mixed-class rows	373,841 mixed-class rows	$212,590	—	28 Feb 2022	3/4/5
Qube Research & Technologies Ltd	13F	Company	0.23%	598,379	$211,000	—	30 Jun 2022	13F
STATE STREET CORP	13F	Company	0.22%	573,876	$203,000	—	30 Jun 2022	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.2%	529,450	$187,000	—	30 Jun 2022	13F
GROUP ONE TRADING LLC	13F	Company	0.18%	467,964	$165,000	—	30 Jun 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.18%	464,948	$164,000	—	30 Jun 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.17%	457,303	$162,000	—	30 Jun 2022	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	0.16%	414,392	$146,000	—	30 Jun 2022	13F
Icon Wealth Partners, LLC	13F	Company	0.15%	400,132	$141,000	—	30 Jun 2022	13F
NORTHERN TRUST CORP	13F	Company	0.14%	360,526	$127,000	—	30 Jun 2022	13F
Bayesian Capital Management, LP	13F	Company	0.12%	304,100	$107,000	—	30 Jun 2022	13F
VOYA INVESTMENT MANAGEMENT LLC	13F	Company	0.11%	301,740	$107,000	—	30 Jun 2022	13F
Invesco Ltd.	13F	Company	0.1%	264,550	$93,000	—	30 Jun 2022	13F
Orchard Capital Management, LLC	13F	Company	0.1%	251,826	$89,000	—	30 Jun 2022	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.1%	250,894	$89,000	—	30 Jun 2022	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.09%	241,349	$85,000	—	30 Jun 2022	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.09%	226,770	$80,000	—	30 Jun 2022	13F
Russell Investments Group, Ltd.	13F	Company	0.09%	225,640	$78,000	—	30 Jun 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.08%	213,549	$75,000	—	30 Jun 2022	13F
Michael Thomas Heffernan	3/4/5	Director	— mixed-class rows	68,686 mixed-class rows	$59,416	—	02 Jun 2021	3/4/5
Allspring Global Investments Holdings, LLC	13F	Company	0.06%	168,942	$59,000	—	30 Jun 2022	13F
JANE STREET GROUP, LLC	13F	Company	0.06%	162,166	$57,000	—	30 Jun 2022	13F
TUDOR INVESTMENT CORP ET AL	13F	Company	0.06%	146,708	$52,000	—	30 Jun 2022	13F
UBS Group AG	13F	Company	0.05%	130,652	$46,000	—	30 Jun 2022	13F
CITIGROUP INC	13F	Company	0.04%	110,287	$39,000	—	30 Jun 2022	13F
Parallax Volatility Advisers, L.P.	13F	Company	0.04%	109,683	$39,000	—	30 Jun 2022	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.03%	90,540	$31,970	—	30 Jun 2022	13F
FRANKLIN RESOURCES INC	13F	Company	0.03%	82,473	$29,000	—	30 Jun 2022	13F
Bank of New York Mellon Corp	13F	Company	0.03%	71,836	$26,000	—	30 Jun 2022	13F
LMR Partners LLP	13F	Company	0.02%	64,849	$23,000	—	30 Jun 2022	13F
EDMOND DE ROTHSCHILD HOLDING S.A.	13F	Company	0.02%	50,000	$18,000	—	30 Jun 2022	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.02%	47,100	$17,000	—	30 Jun 2022	13F
HighTower Advisors, LLC	13F	Company	0.02%	45,724	$16,000	—	30 Jun 2022	13F
MACKENZIE FINANCIAL CORP	13F	Company	0.02%	42,792	$15,000	—	30 Jun 2022	13F

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2022

As of 30 Sep 2022, Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by 79 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 52,161,214 shares. The largest 10 holders included VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, Alerce Investment Management, L.P., BlackRock Inc., MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, FEDERATED HERMES, INC., GEODE CAPITAL MANAGEMENT, LLC, and DIMENSIONAL FUND ADVISORS LP. This page lists 79 institutional shareholders reporting positions in this security for the Q3 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2022 vs Q2 2022 Across Filers

Q2 2022 holders

Q3 2022 holders

Holder diff

-3

Investor	Q2 2022 Shares	Q3 2022 Shares	Share Diff	Share Chg %	Q2 2022 Value $	Q3 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.